These results also indicate that CTLA4 might play a role in hampering the induction of Treg cells with pro-inflammatory TH17-like characteristics, and warrants further investigation to explore whether Abatacept could be used as a targeted therapy in patients with aspergillosis that are suffering from infection-induced immunopathology. Here, CTLA4 is linked to infection.